×

Sellas’ cancer vaccine extends survival in blood cancer trial

By Thomson Reuters Nov 17, 2026 | 6:18 AM

Nov 17 (Reuters) – Sellas Life Sciences said on Tuesday its ​experimental vaccine helped ‌patients with a type of blood cancer live longer in a ‌late-stage ​trial.

The vaccine, ⁠called galinpepimut-S ⁠or GPS, was tested in patients with acute myeloid leukemia, a ​fast-growing cancer of the blood ⁠and bone ⁠marrow.

Patients who received ​GPS lived a median ​of 24 months, compared ‌to 14.7 months for those given the best available treatment, ⁠Sellas said.

The company plans to talk to the ⁠US ‌Food and Drug ⁠Administration about seeking ​approval ‌for the vaccine. ​Its ⁠shares were halted in premarket trading.

(Reporting by Kamal Choudhury in Bengaluru; Editing by Shilpi ​Majumdar)